At PRI, we are harnessing the versatility of nanotechnology and biotechnology (sometimes called nanobiotechnology) in formulating nanoparticles that can benefit humanity by formulating nanoparticles targeted directly to a tumor site or other specific organ within the body and carry a payload of potent drug molecule(s) for treatment.

Nanobiotechnology for Early Detection and Treatment

  • Early detection of different tumor types using nanotechnology-based imaging techniques
  • Targeted delivery of chemotherapeutic agent-loaded nanoparticles for pancreatic, brain, breast, prostate, ovarian, lung, and other cancer types
  • Nano-encapsulation of various natural products for improved pharmacokinetics and pharmacodynamics
  • Conjugation of different targeting agents on nanoparticles’ surface to improve efficacy and safety, such as nanoparticle thyroid agonists and antagonists
  • Nano-targeted delivery to cancer cells and associated cancer stem cells

PRI Drug Discovery Areas Using Nanobiotechnology Platforms

  • Cardiovascular and vascular diseases
    • Regional Atherothrombosis Working Group (ACPHS, AMC, SUNY Nano Sciences, RPI, Wadsworth, and VA at Albany) in Atherosclerosis/Thrombosis toward the establishment of Center for Innovation in the early detection, prevention, and treatment of Atherothrombosis
  • Ophthalmology-related disorders
    • Development of novel angiogenesis inhibitors for the suppression of retinal and choroidal neovascularization for the treatment of diabetic retinopathy and age-related macular degeneration
  • Oncology and Hematological disorders
  • Inflammatory diseases
    • Development of novel therapy for acute and chronic inflammatory disorders
  • Neurological disorders
    • Targeted delivery of novel target for neurological disorders

PRI Drug Development Areas Using Nanobiotechnology Platforms

  • Nanoformulation and drug delivery
    • Reformulation of existing generic pharmaceuticals
    • Nanoformulation of new drug targets